The global atherosclerosis therapeutics market size was valued at USD 5.77 billion in 2024 and is expected to reach USD 11.01 billion by 2032, at a CAGR of 8.39% during the forecast period
The market growth is largely fueled by the increasing prevalence of cardiovascular diseases, advancements in drug development, and rising focus on personalized medicine, leading to improved treatment outcomes in both developed and emerging regions
Furthermore, rising demand for effective, safe, and targeted
therapies for atherosclerosis is positioning novel therapeutics and combination treatments as preferred solutions. These converging factors are accelerating the adoption of advanced atherosclerosis therapeutics, thereby significantly boosting the industry's growth